-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
16	O
-	O
week	O
study	O
of	O
the	B-I
H3	I-I
receptor	I-I
antagonist	I-I
,	O
GSK239512	B-I
as	O
a	O
monotherapy	O
in	O
subjects	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
In	O
this	O
16	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
parallel	O
group	O
study	O
,	O
196	B-P
currently	I-P
untreated	I-P
subjects	I-P
with	I-P
mild	I-P
-	I-P
tomoderate	I-P
AD	I-P
(	I-P
Mini	I-P
Mental	I-P
State	I-P
Examination	I-P
[	I-P
MMSE	I-P
]	I-P
16	I-P
-	I-P
24	I-P
)	I-P
received	O
GSK239512	B-I
(	O
n=97	O
)	O
;	O
or	O
placebo	B-C
(	O
n=99	O
)	O
administered	O
orally	O
each	O
morning	O
.	O

After	O
a	O
two	O
-	O
week	O
placebo	O
run	O
-	O
in	O
period	O
GSK239512	O
was	O
up	O
-	O
titrated	O
over	O
4	O
weeks	O
in	O
a	O
flexible	O
manner	O
(	O
10-20-40	O
-	O
80	O
microgram	O
[	O
g	O
]	O
)	O
followed	O
by	O
a	O
12	O
-	O
week	O
Maintenance	O
Phase	O
.	O

Co	O
-	O
primary	O
efficacy	O
endpoints	O
were	O
change	O
from	O
baseline	O
in	O
Episodic	B-O
Memory	I-O
and	O
Executive	B-O
Function	I-O
/	O
Working	B-O
Memory	I-O
composite	I-O
scores	I-O
from	O
the	B-O
CogState	I-O
neuropsychological	I-O
test	I-O
battery	I-O
(	I-O
NTB	I-O
)	I-O
at	O
Week	O
16	O
.	O

-DOCSTART-	O

Title	O
:	O
Taste	B-I
-	I-I
masked	I-I
and	I-I
affordable	I-I
donepezil	I-I
hydrochloride	I-I
orally	O
disintegrating	O
tablet	O
as	O
promising	O
solution	O
for	O
non	O
-	O
compliance	O
in	O
Alzheimer	B-P
'	I-P
s	I-P
disease	I-P
patients	I-P
.	O

METHODS	O
:	O
The	B-I
ODT	I-I
was	O
manufactured	O
using	O
simple	O
wet	O
-	O
granulation	O
method	O
.	O

Crospovidone	O
XL	O
-	O
10	O
was	O
used	O
as	O
superdisintegrant	O
and	O
optimization	O
was	O
done	O
by	O
comparing	O
the	O
effect	O
of	O
three	B-I
grades	I-I
of	I-I
lactose	I-I
monohydrate	I-I
compound	I-I
as	O
filler	O
:	O
Starlac	B-I
,	O
Flowlac	B-I
and	O
Tablettose	B-I
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
citalopram	B-I
on	O
agitation	O
in	O
Alzheimer	O
disease	O
:	O
the	O
CitAD	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
The	B-I
Citalopram	I-I
for	O
Agitation	O
in	O
Alzheimer	O
Disease	O
Study	O
(	O
CitAD	O
)	O
was	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
group	O
trial	O
that	O
enrolled	O
186	B-P
patients	I-P
with	I-P
probable	I-P
Alzheimer	I-P
disease	I-P
and	I-P
clinically	I-P
significant	I-P
agitation	I-P
from	I-P
8	I-P
academic	I-P
centers	I-P
in	I-P
the	I-P
United	I-P
States	I-P
and	I-P
Canada	I-P
from	I-P
August	I-P
2009	I-P
to	I-P
January	I-P
2013	I-P
.	O

Participants	B-P
(	I-P
n	I-P
=	I-P
186	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
a	B-I
psychosocial	I-I
intervention	I-I
plus	O
either	O
citalopram	B-I
(	O
n	O
=	O
94	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
92	O
)	O
for	O
9	O
weeks	O
.	O

Dosage	O
began	O
at	O
10	O
mg	O
per	O
day	O
with	O
planned	O
titration	O
to	O
30	O
mg	O
per	O
day	O
over	O
3	O
weeks	O
based	O
on	O
response	O
and	O
tolerability	O
.	O

Primary	O
outcome	O
measures	O
were	O
based	O
on	O
scores	O
from	O
the	B-O
18	I-O
-	I-O
point	I-O
Neurobehavioral	I-O
Rating	I-O
Scale	I-O
agitation	I-O
subscale	I-O
(	I-O
NBRS	I-O
-	I-O
A	I-O
)	I-O
and	O
the	B-O
modified	I-O
Alzheimer	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
mADCS	I-O
-	I-O
CGIC	I-O
)	I-O
.	O

Other	O
outcomes	O
were	O
based	O
on	O
scores	O
from	O
the	B-O
Cohen	I-O
-	I-O
Mansfield	I-O
Agitation	I-O
Inventory	I-O
(	I-O
CMAI	I-O
)	I-O
and	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
,	O
ability	B-O
to	I-O
complete	I-O
activities	I-O
of	I-O
daily	I-O
living	I-O
(	I-O
ADLs	I-O
)	I-O
,	O
caregiver	B-O
distress	I-O
,	O
cognitive	B-O
safety	I-O
(	O
based	O
on	O
scores	O
from	O
the	B-O
30	I-O
-	I-O
point	I-O
Mini	I-O
Mental	I-O
State	I-O
Examination	I-O
[	I-O
MMSE	I-O
]	I-O
)	O
,	O
and	O
adverse	B-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Rivastigmine	B-I
transdermal	I-I
patch	I-I
and	O
physical	B-I
exercises	I-I
for	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
controlled	O
,	O
single	O
-	O
blinded	O
trial	O
was	O
conducted	O
in	O
40	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
stages	I-P
of	I-P
AD	I-P
.	O

All	O
patients	O
were	O
daily	O
treated	O
with	O
rivastigmine	B-I
transdermal	I-I
patch	I-I
at	O
a	O
stable	O
dose	O
of	O
4	O
.	O
6	O
mg	O
and	O
randomized	O
into	O
two	O
groups	O
:	O
physical	B-I
exercises	I-I
or	O
control	O
.	O

The	B-I
exercise	I-I
program	I-I
consisted	O
of	O
aerobic	B-I
,	O
flexibility	B-I
,	O
strength	B-I
and	O
balance	B-I
movements	I-I
,	O
twice	O
a	O
week	O
for	O
6	O
months	O
.	O

Main	O
outcomes	O
were	O
Quality	B-O
of	I-O
Life	I-O
in	I-O
Alzheimer	I-O
'	I-O
s	I-O
disease	I-O
scale	I-O
(	I-O
QOL	I-O
)	I-O
,	O
Activities	B-O
of	I-O
Daily	I-O
Living	I-O
Questionnaire	I-O
(	I-O
ADL	I-O
)	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
and	O
"	B-O
Time	I-O
Up	I-O
and	I-O
Go	I-O
Test	I-O
"	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Add	B-I
-	I-I
on	I-I
prolonged	I-I
-	I-I
release	I-I
melatonin	I-I
for	O
cognitive	O
function	O
and	O
sleep	O
in	O
mild	O
to	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
6	O
-	O
month	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
trial	O
.	O

METHODS	O
:	O
The	O
effects	O
of	O
add	B-I
-	I-I
on	I-I
prolonged	I-I
-	I-I
release	I-I
melatonin	I-I
(	I-I
PRM	I-I
)	I-I
(	O
2	O
mg	O
)	O
to	O
standard	B-C
therapy	I-C
on	O
cognitive	O
functioning	O
and	O
sleep	O
were	O
investigated	O
in	O
80	B-P
patients	I-P
(	I-P
men	I-P
[	I-P
50	I-P
.	I-P
7	I-P
%	I-P
]	I-P
,	I-P
women	I-P
[	I-P
49	I-P
.	I-P
3	I-P
%	I-P
]	I-P
,	I-P
average	I-P
age	I-P
75	I-P
.	I-P
3	I-P
years	I-P
[	I-P
range	I-P
,	I-P
52	I-P
-	I-P
85	I-P
years	I-P
]	I-P
)	I-P
diagnosed	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
,	I-P
with	I-P
and	I-P
without	I-P
insomnia	I-P
comorbidity	I-P
,	I-P
and	I-P
receiving	I-P
standard	I-P
therapy	I-P
(	I-P
acetylcholinesterase	I-P
inhibitors	I-P
with	I-P
or	I-P
without	I-P
memantine	I-P
)	I-P
.	O

In	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
study	O
,	O
patients	O
were	O
treated	O
for	O
2	O
weeks	O
with	O
placebo	B-C
and	O
then	O
randomized	O
(	O
1	O
:	O
1	O
)	O
to	O
receive	O
2	B-I
mg	I-I
of	I-I
PRM	I-I
or	O
placebo	B-C
nightly	O
for	O
24	O
weeks	O
,	O
followed	O
by	O
2	B-C
weeks	I-C
placebo	I-C
.	O

The	B-O
AD	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognition	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
,	O
Instrumental	B-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
(	I-O
IADL	I-O
)	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
sleep	B-O
,	O
as	O
assessed	O
by	O
the	B-O
Pittsburgh	I-O
Sleep	I-O
Quality	I-O
Index	I-O
(	I-O
PSQI	I-O
)	I-O
and	O
a	B-O
daily	I-O
sleep	I-O
diary	I-O
,	O
and	O
safety	B-O
parameters	I-O
were	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
tolerability	O
of	O
immune	B-I
globulin	I-I
intravenous	I-I
(	I-I
human	I-I
)	I-I
,	O
10	O
%	O
solution	O
in	O
Japanese	B-P
subjects	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Among	O
the	B-P
16	I-P
subjects	I-P
,	O
12	O
subjects	O
were	O
assigned	O
to	O
the	B-I
IGIV	I-I
group	O
and	O
4	O
subjects	O
to	O
the	B-C
placebo	I-C
group	O
.	O

Subjects	O
received	O
a	O
total	O
of	O
six	O
infusions	O
of	O
either	O
IGIV	B-I
at	O
a	O
dose	O
of	O
0	O
.	O
2	O
or	O
0	O
.	O
4	O
g	O
/	O
kg	O
,	O
or	O
placebo	B-C
every	O
2	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
single	O
-	O
dose	O
pilot	O
trial	O
of	O
intranasal	B-I
rapid	I-I
-	I-I
acting	I-I
insulin	I-I
in	O
apolipoprotein	B-P
E4	I-P
carriers	I-P
with	I-P
mild	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
We	O
performed	O
a	O
double	O
-	O
blinded	O
,	O
randomized	O
,	O
cross	O
-	O
over	O
study	O
of	O
RA	B-I
insulin	I-I
glulisine	I-I
in	O
nine	B-P
mild	I-P
-	I-P
moderate	I-P
AD	I-P
subjects	I-P
to	O
better	O
understand	O
the	O
relationship	O
between	O
RA	B-O
insulin	I-O
,	O
ApoE4	B-O
carrier	I-O
status	I-O
and	O
memory	B-O
performance	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Donepezil	B-I
decreases	O
annual	O
rate	O
of	O
hippocampal	O
atrophy	O
in	O
suspected	O
prodromal	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
parallel	O
group	O
design	O
using	O
donepezil	B-I
(	O
10	O
mg	O
/	O
day	O
)	O
in	O
subjects	B-P
with	I-P
suspected	I-P
prodromal	I-P
AD	I-P
.	O

Subjects	O
underwent	O
two	O
brain	O
magnetic	O
resonance	O
imaging	O
scans	O
(	O
baseline	O
and	O
final	O
visit	O
)	O
.	O

The	O
primary	O
efficacy	O
outcome	O
was	O
the	O
annualized	O
percentage	O
change	O
(	O
APC	O
)	O
of	O
total	B-O
hippocampal	I-O
volume	I-O
(	I-O
left	I-O
+	I-O
right	I-O
)	I-O
measured	O
by	O
an	B-O
automated	I-O
segmentation	I-O
method	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Characterization	O
of	O
hepatic	O
enzyme	O
activity	O
in	O
older	B-P
adults	I-P
with	I-P
dementia	I-P
:	O
potential	O
impact	O
on	O
personalizing	O
pharmacotherapy	O
.	O

METHODS	O
:	O
A	O
multisite	O
cross	O
-	O
sectional	O
study	O
was	O
carried	O
out	O
across	O
four	O
memory	O
care	O
practices	O
in	O
the	O
greater	O
Indianapolis	O
area	O
.	O

Participants	O
were	O
adults	B-P
aged	I-P
65	I-P
years	I-P
and	I-P
older	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
probable	I-P
or	I-P
possible	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
AD	I-P
)	I-P
(	I-P
n=105	I-P
)	I-P
.	O

Blood	O
samples	O
and	O
self	O
-	O
reported	O
medication	O
data	O
were	O
collected	O
.	O

Since	O
two	O
of	O
the	O
three	O
AChEIs	O
are	O
metabolized	O
by	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
-	O
2D6	O
,	O
we	O
determined	O
the	B-O
frequency	I-O
of	I-O
functional	I-O
genetic	I-O
variants	I-O
in	I-O
the	I-O
CYP2D6	I-O
gene	I-O
and	O
calculated	O
their	B-O
predicted	I-O
CYP2D6	I-O
-	I-O
activity	I-O
scores	I-O
.	O

Concurrent	O
medication	O
data	O
were	O
collected	O
from	O
self	O
-	O
reported	O
medication	O
surveys	O
,	O
and	O
their	O
predicted	O
effect	O
on	O
the	B-O
pharmacokinetics	I-O
of	I-O
AChEIs	I-O
was	O
determined	O
based	O
on	O
their	O
known	O
effects	O
on	O
CYP2D6	B-O
and	O
CYP3A4	B-O
/	I-O
5	I-O
enzyme	I-O
activities	I-O
.	O

-DOCSTART-	O

Title	O
:	O
First	O
administration	O
of	O
the	B-I
Fc	I-I
-	I-I
attenuated	I-I
anti	I-I
-	I-I
?	I-I
amyloid	I-I
antibody	I-I
GSK933776	I-I
to	O
patients	B-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
two	O
-	O
part	O
,	O
single	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
first	O
-	O
time	O
-	O
in	O
-	O
human	O
(	O
FTIH	O
)	O
study	O
of	O
single	B-I
(	O
n	O
=	O
18	O
)	O
and	O
repeat	B-I
dose	I-I
(	I-I
n	I-I
=	I-I
32	I-I
)	I-I
intravenous	I-I
GSK933776	I-I
0	O
.	O
001	O
-	O
6	O
mg	O
/	O
kg	O
(	O
ClinicalTrials	O
.	O
gov	O
:	O
NCT00459550	O
)	O
.	O

Additional	O
safety	O
data	O
from	O
an	O
open	O
-	O
label	O
,	O
uncontrolled	O
,	O
single	B-I
dose	I-I
study	I-I
of	I-I
intravenous	I-I
GSK933776	I-I
1	O
-	O
6	O
mg	O
/	O
kg	O
(	O
n	O
=	O
18	O
)	O
are	O
included	O
(	O
ClinicalTrials	O
.	O
gov	O
:	O
NCT01424436	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Tailored	B-I
nutritional	I-I
guidance	I-I
for	O
home	B-P
-	I-P
dwelling	I-P
AD	I-P
families	I-P
:	O
the	O
Feasibility	O
of	O
and	O
Elements	O
Promoting	O
Positive	O
Changes	O
in	O
Diet	O
(	O
NuAD	O
-	O
Trial	O
)	O
.	O

METHODS	O
:	O
This	O
qualitative	O
study	O
comprised	O
40	B-P
persons	I-P
with	I-P
AD	I-P
and	I-P
spousal	I-P
caregivers	I-P
of	I-P
our	I-P
trial	I-P
.	O

Our	O
intervention	O
during	O
one	O
year	O
involved	O
tailored	B-I
nutritional	I-I
guidance	I-I
for	O
these	O
couples	O
.	O

The	B-I
nutritionist	I-I
'	I-I
s	I-I
field	I-I
notes	I-I
(	O
about	O
100	O
pages	O
)	O
and	O
the	B-I
participant	I-I
feedback	I-I
questionnaires	I-I
(	O
N	O
=	O
28	O
)	O
served	O
to	O
analyse	O
the	O
feasibility	B-O
of	I-O
intervention	I-O
,	O
factors	B-O
promoting	I-O
the	I-O
application	I-O
of	I-O
intervention	I-O
and	O
challenges	B-O
hindering	I-O
it	I-O
.	O

Thematic	O
content	O
analysis	O
served	O
to	O
analyse	O
our	O
data	O
with	O
the	O
grounded	O
theory	O
approach	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Clinical	O
observation	O
of	O
Alzheimer	O
'	O
s	O
disease	O
treated	O
with	O
acupuncture	B-I
]	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
forty	I-P
-	I-P
one	I-P
patients	I-P
were	O
randomized	O
into	O
an	B-I
acupuncture	I-I
group	O
(	O
72	O
cases	O
)	O
and	O
a	B-I
medicine	I-I
group	O
(	O
69	O
cases	O
)	O
.	O

In	O
the	B-I
acupuncture	I-I
group	O
,	O
the	O
needling	O
technique	O
for	O
benefiting	O
qi	O
,	O
promoting	O
blood	O
circulation	O
,	O
regulating	O
mind	O
and	O
improving	O
intelligence	O
was	O
used	O
at	O
Shenting	O
(	O
GV	O
24	O
)	O
,	O
Baihui	O
(	O
GV	O
20	O
)	O
,	O
Fengchi	O
(	O
GB	O
20	O
)	O
,	O
Wangu	O
(	O
GB	O
12	O
)	O
,	O
Danzhong	O
(	O
CV	O
17	O
)	O
,	O
Zhangwan	O
(	O
CV	O
12	O
)	O
,	O
Qihai	O
(	O
CV	O
6	O
)	O
,	O
Xuehai	O
(	O
SP	O
10	O
)	O
and	O
Zusanli	O
(	O
ST	O
36	O
)	O
.	O

The	O
supplementary	O
acupoints	O
were	O
selected	O
according	O
to	O
the	O
symptoms	O
and	O
physical	O
signs	O
.	O

Acupuncture	O
was	O
given	O
once	O
a	O
day	O
and	O
6	O
treatments	O
were	O
required	O
for	O
a	O
week	O
.	O

In	O
the	B-I
medicine	I-I
group	O
,	O
the	B-I
choline	I-I
sterase	I-I
inhibitor	I-I
,	O
donepezil	B-I
(	I-I
aricept	I-I
)	I-I
was	O
prescribed	O
for	O
oral	O
administration	O
,	O
1	O
tablet	O
(	O
5	O
mg	O
)	O
each	O
time	O
,	O
once	O
every	O
night	O
.	O

Four	O
weeks	O
later	O
,	O
the	O
dose	O
was	O
increased	O
to	O
2	O
tablets	O
(	O
10	O
mg	O
)	O
each	O
time	O
.	O

In	O
the	O
two	O
groups	O
,	O
the	O
treatment	O
of	O
4	O
weeks	O
made	O
one	O
session	O
and	O
4	O
sessions	O
were	O
required	O
.	O

The	O
changes	O
of	O
scores	O
before	O
and	O
after	O
treatment	O
in	O
the	B-O
minimum	I-O
mental	I-O
state	I-O
examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
the	B-O
activity	I-O
of	I-O
daily	I-O
living	I-O
scale	I-O
(	I-O
ADL	I-O
)	I-O
,	O
Alzheimer	B-O
'	I-O
s	I-O
disease	I-O
assessment	I-O
scale	I-O
-	I-O
cognition	I-O
(	I-O
ADAS	I-O
-	I-O
cog	I-O
)	I-O
and	O
the	B-O
digit	I-O
span	I-O
(	I-O
DS	I-O
)	I-O
were	O
observed	O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
web	I-I
-	I-I
based	I-I
psychoeducational	I-I
program	I-I
for	O
informal	B-P
caregivers	I-P
of	I-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
a	O
pilot	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
recruited	O
and	O
randomized	O
offline	O
49	B-P
informal	I-P
caregivers	I-P
of	I-P
a	I-P
PWAD	I-P
in	I-P
a	I-P
day	I-P
care	I-P
center	I-P
in	I-P
Paris	I-P
,	I-P
France	I-P
.	O

They	O
either	O
received	O
the	B-I
Web	I-I
-	I-I
based	I-I
intervention	I-I
and	O
usual	B-C
care	I-C
for	O
3	O
months	O
(	O
experimental	O
group	O
,	O
n=25	O
)	O
or	O
only	B-C
usual	I-C
care	I-C
(	O
control	O
group	O
,	O
n=24	O
)	O
.	O

Caregivers	B-O
'	I-O
perceived	I-O
stress	I-O
(	O
PSS	B-O
-	I-O
14	I-O
,	O
primary	O
outcome	O
)	O
,	O
self	B-O
-	I-O
efficacy	I-O
,	O
burden	B-O
,	O
perceived	B-O
health	I-O
status	I-O
,	O
and	O
depression	B-O
(	O
secondary	O
outcomes	O
)	O
were	O
measured	O
during	O
3	O
face	O
-	O
to	O
-	O
face	O
on	O
-	O
site	O
visits	O
:	O
at	O
baseline	O
,	O
at	O
the	O
end	O
of	O
the	O
program	O
(	O
month	O
3	O
)	O
,	O
and	O
after	O
follow	O
-	O
up	O
(	O
month	O
6	O
)	O
.	O

Additionally	O
,	O
semistructured	O
interviews	O
were	O
conducted	O
with	O
experimental	O
group	O
caregivers	O
at	O
month	O
6	O
and	O
examined	O
with	O
thematic	O
analysis	O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	O
Improvement	O
during	O
Treatment	O
for	O
Mild	O
Alzheimer	O
'	O
s	O
Disease	O
with	O
a	B-I
Chinese	I-I
Herbal	I-I
Formula	I-I
:	O
A	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
mild	I-P
AD	I-P
meeting	I-P
the	I-P
criteria	I-P
were	O
randomized	O
into	O
Chinese	B-I
herbal	I-I
formula	I-I
Yishen	I-I
Huazhuo	I-I
decoction	I-I
(	I-I
YHD	I-I
)	I-I
group	O
and	O
donepezil	B-I
hydrochloride	I-I
(	I-I
DH	I-I
)	I-I
group	O
during	O
the	O
24	O
-	O
week	O
trial	O
.	O

The	O
outcomes	O
were	O
measured	O
by	O
ADAS	B-O
-	I-O
cog	I-O
,	O
MMSE	B-O
,	O
ADL	B-O
,	O
and	O
NPI	B-O
with	O
linear	O
mixed	O
-	O
effect	O
models	O
.	O

-DOCSTART-	O

Title	O
:	O
Early	B-I
psychosocial	I-I
intervention	I-I
does	O
not	O
delay	O
institutionalization	O
in	O
persons	B-P
with	I-P
mild	I-P
Alzheimer	I-P
disease	I-P
and	O
has	O
impact	O
on	O
neither	O
disease	O
progression	O
nor	O
caregivers	O
'	O
well	O
-	O
being	O
:	O
ALSOVA	O
3	O
-	O
year	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
Kuopio	O
ALSOVA	O
study	O
,	O
a	O
prospective	O
,	O
randomized	O
intervention	O
study	O
with	O
a	O
3	O
-	O
year	O
follow	O
-	O
up	O
,	O
was	O
carried	O
out	O
at	O
memory	O
clinics	O
.	O

Home	B-P
-	I-P
dwelling	I-P
persons	I-P
with	I-P
very	I-P
mild	I-P
or	I-P
mild	I-P
AD	I-P
(	I-P
n	I-P
=	I-P
236	I-P
)	I-P
and	I-P
AD	I-P
-	I-P
targeted	I-P
therapy	I-P
and	I-P
their	I-P
family	I-P
caregivers	I-P
(	I-P
n	I-P
=	I-P
236	I-P
)	I-P
were	O
randomized	O
to	O
the	O
intervention	O
or	O
control	O
group	O
(	O
1	O
:	O
2	O
)	O
.	O

Psychosocial	B-I
intervention	I-I
including	O
education	B-I
,	O
counseling	B-I
,	O
and	O
social	B-I
support	I-I
was	O
given	O
during	O
the	O
first	O
2	O
years	O
(	O
16	O
days	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
cumulative	I-O
risk	I-O
(	I-O
controlled	I-O
for	I-O
death	I-O
)	I-O
of	O
institutionalization	O
over	O
36	O
months	O
.	O

Secondary	O
outcomes	O
were	O
adjusted	O
mean	O
changes	O
from	O
baseline	O
in	O
disease	B-O
severity	I-O
,	O
cognition	B-O
,	O
daily	B-O
activities	I-O
,	O
behavior	B-O
,	O
and	O
HRQoL	B-O
for	O
persons	B-P
with	I-P
AD	I-P
;	O
and	O
change	O
in	O
psychological	B-O
distress	I-O
,	O
depression	B-O
,	O
and	O
HRQoL	B-O
for	O
caregivers	B-P
.	O

